Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF
The ability of S-Acetyl-L-glutathione to be directly absorbed by cells and converted to GSH without needing breakdown into amino acids presents a significant advantage, especially in conditions where GSH synthesis may be impaired, such as during viral infections or in genetic disorders affecting GSH metabolism
Side Effects of Semaglutide and Tirzepatide Common side effects for both drugs include nausea, vomiting, and diarrhea , though the intensity and frequency can differ between the two
Key Findings: Large human studies across multiple countries have not found increased thyroid cancer rates in GLP-1 users The FDA warning applies to medullary thyroid carcinoma (MTC)only 3-4% of all thyroid cancers The warning exists because rodents developed C-cell tumors, but humans and rodents differ biologically Some studies show associations, but these are explained by detection bias (more monitoring = finding pre-existing nodules) The Clayman Thyroid Center (2,000+ thyroid cancer patients/year) has not seen an MTC pattern linked to GLP-1 use (or for that matter any other thyroid malignancy) Clinical Recommendations: Patients with MTC history or MEN2 should not take GLP-1 receptor agonists Patients with common thyroid cancers (papillary, follicular, Hrthle cell) should not assume GLP-1 caused them or will have an effect upon them Decisions should be individualized, weighing metabolic benefits against theoretical concerns GLP-1 therapy does not require additional thyroid monitoring Quick Reference for Clinicians Understanding the Question What Medications Are We Discussing
Epidemiological evidence In a meta-analysis comparing new-onset HF among normal-weight and overweight patients, being overweight increased the risk of developing HF by 33%
